Drugs / GAIA-102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05608148 | Oct 2022 → Aug 2027 expected | childhood malignant neoplasm, neuroblastoma | Kyushu University | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05438459 | Jun 2022 → Dec 2028 expected | gastric cancer, malignant pancreatic neoplasm | Kyushu University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05207371 | Dec 2021 → Oct 2022 | non-small cell lung carcinoma | GAIA BioMedicine Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAIA-102 | “Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.” NCT05438459 ↗2“Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗ “Intravenous injection of GAIA-102 alone” NCT05608148 ↗ |
| Modality | Cell therapy | “1 vial (2 x 10\^8 cells) / dose at a fixed dose” NCT05207371 ↗ |
| Route | Intravenous | “Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)” NCT05207371 ↗ |